Silverarc Capital Management, LLC Bellus Health Inc. Transaction History

Silverarc Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.14 - $8.53 $5.05 Million - $6.03 Million	-707,370 Reduced 41.43%	1,000,000 $7.2 Million
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $424,110 - $555,162	51,595 Added 3.12%	1,707,370 $14 Million
Q3 2022 Oct 28, 2022	BUY	$8.95 - $12.0 $830,721 - $1.11 Million	92,818 Added 5.94%	1,655,775 $17.5 Million
Q2 2022 Jul 25, 2022	BUY	$6.46 - $10.02 $2.11 Million - $3.28 Million	327,173 Added 26.47%	1,562,957 $14.4 Million
Q1 2022 May 13, 2022	BUY	$5.56 - $7.99 $754,959 - $1.08 Million	135,784 Added 12.34%	1,235,784 $177,000
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $3.87 Million - $6.1 Million	735,000 Added 201.37%	1,100,000 $8.86 Million
Q3 2021 Nov 15, 2021	BUY	$2.7 - $6.64 $418,680 - $1.03 Million	155,067 Added 73.86%	365,000 $2.24 Million
Q2 2021 Aug 16, 2021	BUY	$3.11 - $4.61 $652,891 - $967,791	209,933 New	209,933 $653,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.